{"id":"rituximab-arm-a","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections"},{"rate":"10-30","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers multiple mechanisms of B cell death including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This results in rapid depletion of B cells, reducing autoimmune and malignant B cell populations.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:20.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"},{"name":"Rheumatoid arthritis"},{"name":"Granulomatosis with polyangiitis"},{"name":"Microscopic polyangiitis"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT04840602","phase":"PHASE2","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-01-05","conditions":"Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia","enrollment":92},{"nctId":"NCT01886872","phase":"PHASE3","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-15","conditions":"Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia","enrollment":547},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT04998669","phase":"PHASE2","title":"Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2022-02-11","conditions":"Follicular Lymphoma","enrollment":100},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT06943872","phase":"PHASE3","title":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-06-11","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":630},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":"CLL, Chronic Lymphocytic Leukemia","enrollment":250},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT04931368","phase":"PHASE3","title":"OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klinikum Stuttgart","startDate":"2021-06-28","conditions":"Primary Central Nervous System Lymphoma","enrollment":331},{"nctId":"NCT06561360","phase":"PHASE2","title":"A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-09","conditions":"Hairy Cell Leukemia","enrollment":86},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT07475754","phase":"NA","title":"A Study to Evaluate the Safety and Tolerability of Rituxan in Duchenne Muscular Dystrophy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-03-23","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":5},{"nctId":"NCT02203526","phase":"PHASE1","title":"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-14","conditions":"Primary Central Nervous System Lymphoma","enrollment":93},{"nctId":"NCT01419561","phase":"PHASE2","title":"Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-08","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8","enrollment":140},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT03458260","phase":"PHASE2","title":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-12-26","conditions":"Aggressive Non-Hodgkin Lymphoma","enrollment":74},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":590},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT05581030","phase":"PHASE1","title":"CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT06321601","phase":"PHASE3","title":"Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-10-22","conditions":"Vasculitis","enrollment":20},{"nctId":"NCT06475495","phase":"PHASE1, PHASE2","title":"Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-12-04","conditions":"Rheumatoid Arthritis","enrollment":13},{"nctId":"NCT07335562","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2026-04-30","conditions":"Systemic Sclerosis","enrollment":92},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT05976763","phase":"PHASE3","title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-20","conditions":"Mantle Cell Lymphoma","enrollment":421},{"nctId":"NCT07448324","phase":"PHASE2","title":"Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":50},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT04231877","phase":"PHASE1","title":"Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-10-27","conditions":"Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":56},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06508658","phase":"PHASE3","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-08-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":360},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT03150693","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2017-09-20","conditions":"B Acute Lymphoblastic Leukemia","enrollment":310},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT04268277","phase":"PHASE2","title":"Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY","status":"TERMINATED","sponsor":"University of Ulm","startDate":"2022-03-01","conditions":"Marginal Zone Lymphoma","enrollment":22},{"nctId":"NCT01473628","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-05-20","conditions":"Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Follicular Lymphoma","enrollment":81},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT06651970","phase":"PHASE4","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukaemia, Heart Failure","enrollment":60},{"nctId":"NCT06655896","phase":"PHASE2","title":"Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-29","conditions":"Scleroderma, Diffuse","enrollment":96},{"nctId":"NCT05991388","phase":"PHASE2, PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":210},{"nctId":"NCT05898308","phase":"PHASE4","title":"Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-12-04","conditions":"Pemphigus, Dermatologic Disease","enrollment":133},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT04554914","phase":"PHASE2","title":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2021-07-14","conditions":"Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)","enrollment":190},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT05551936","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaishalee Kenkre","startDate":"2023-01-26","conditions":"Follicular Lymphoma","enrollment":42},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT07405255","phase":"PHASE2","title":"Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-30","conditions":"Central Nervous System Lymphoma","enrollment":19},{"nctId":"NCT06517511","phase":"PHASE2","title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT06644183","phase":"PHASE1, PHASE2","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"Jennifer R. Brown, MD, PhD","startDate":"2025-03-19","conditions":"Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia","enrollment":64},{"nctId":"NCT07397832","phase":"PHASE2","title":"CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":58},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT07387848","phase":"PHASE2","title":"Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"American University of Beirut Medical Center","startDate":"2026-04-15","conditions":"Diffuse Large B Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT04712097","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-27","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":478},{"nctId":"NCT05660369","phase":"PHASE1","title":"CARv3-TEAM-E T Cells in Glioblastoma","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-03-22","conditions":"Glioblastoma, Malignant Glioma, Recurrent Glioblastoma","enrollment":21},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":63},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT04965493","phase":"PHASE3","title":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-20","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":600},{"nctId":"NCT07371923","phase":"PHASE2","title":"Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-11-20","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT02900976","phase":"PHASE2","title":"Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2017-03-22","conditions":"EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder","enrollment":18},{"nctId":"NCT04196413","phase":"PHASE1","title":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-06-04","conditions":"Glioma of Spinal Cord, Glioma of Brainstem","enrollment":97},{"nctId":"NCT07233330","phase":"PHASE2","title":"Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-02","conditions":"Nephrotic Syndrome，Idiopathic","enrollment":10},{"nctId":"NCT07362199","phase":"PHASE2","title":"Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Immune Thrombocytopenia, Treatment","enrollment":20},{"nctId":"NCT05023980","phase":"PHASE3","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-23","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":309},{"nctId":"NCT06342544","phase":"PHASE3","title":"Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04-29","conditions":"Ocular Myasthenia Gravis","enrollment":128},{"nctId":"NCT07355699","phase":"PHASE4","title":"Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-11-25","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":88},{"nctId":"NCT06647732","phase":"PHASE2","title":"Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-30","conditions":"Mucosa-associated Lymphoid Tissue Lymphoma (MALT)","enrollment":42},{"nctId":"NCT05735834","phase":"PHASE3","title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2024-05-21","conditions":"Splenic Marginal Zone Lymphoma","enrollment":122},{"nctId":"NCT01599559","phase":"NA","title":"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2012-10","conditions":"Primary Mediastinal B-cell Lymphoma","enrollment":540},{"nctId":"NCT04486716","phase":"PHASE3","title":"A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-19","conditions":"Relapsing Multiple Sclerosis","enrollment":111},{"nctId":"NCT06970743","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-05-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":150},{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":"Diffuse Large B-cell Lymphoma","enrollment":260},{"nctId":"NCT01350882","phase":"PHASE3","title":"Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2008-10","conditions":"Humoral Rejection in Kidney Transplantation","enrollment":40},{"nctId":"NCT03467867","phase":"PHASE2","title":"A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2018-04-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":25},{"nctId":"NCT07299331","phase":"NA","title":"Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Zhengzhou University","startDate":"2026-01-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":50},{"nctId":"NCT05952024","phase":"PHASE2","title":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rituximab (Arm A)","genericName":"Rituximab (Arm A)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a binding agent that targets the B-lymphocyte antigen CD20. It is used to treat various conditions, including Primary Extranodal Lymphoma, DLBCL, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, and Stage I Chronic Lymphocytic Leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}